NewsRoom Articles - Page 32 of 214

MondayAug 12, 2024 10:00 am

Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease

Parkinson’s disease is a progressive condition that affects an individual’s nervous system and the body parts controlled by the nerves. Scientifically speaking, the disease is brought on by neuronal damage caused by too much production of reactive oxygen species. Damage mainly affects neurons that produce dopamine, which plays a role in cognitive function and motor control. The condition usually gets worse over time, with the first symptom often being a tremor in the hands. Other symptoms include painful muscle contractions, tremors, and difficulty speaking. As the population globally grows older, the number of individuals suffering from Parkinson’s continues to increase.…

MondayAug 12, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43 TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with…

FridayAug 09, 2024 10:00 am

Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies

Australia recently launched a countrywide immunotherapy program for infants with peanut allergies. The program is a partnership between the Murdoch Children’s Research Institute and the country’s National Allergy Center of Excellence. This is the first time a countrywide program for peanut allergies is being integrated into mainstream care globally. The program, whose objective is to safely build tolerance and hopefully achieve remission, is available for babies under 12 months who have been diagnosed with peanut allergies. The infants must be under the care of an allergy specialist in one of the 10 public pediatric hospitals across the states taking part…

FridayAug 09, 2024 9:45 am

Astiva Health Inc. Focused on Establishing Lifelong Relationships, Providing Tailored Healthcare Approach to Underserved Populations

Survey indicates sizable proportion of older adult population copes with healthcare costs by skipping treatments, cutting back on basic and essential needs Astiva Health is keenly aware of problems faced by underserved senior population The company strives to bridge healthcare gaps through proactive, culturally responsive solutions As growing numbers of the U.S. population reach age 65, the challenge of adequate healthcare becomes even more critical. In fact, a West Health-Gallup survey reports that some elderly are forgoing needed care because of healthcare costs (https://ibn.fm/pJGqA). Astiva Health, a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) health plan, is on a mission…

WednesdayAug 07, 2024 10:00 am

Snycio, Vevol Media Partner to Transform eCommerce Store Management

Recently, Syncio entered into a partnership agreement with Vevol Media to streamline e-commerce operations for businesses by integrating different sales channels. Syncio has, for a while now, been streamlining e-commerce operations for merchants on WooCommerce and Shopify. The company is focused on efficiency and simplicity, while Vevol Media specializes in assisting businesses to thrive in the digital marketplace. Vevol, a leading partner of Shopify, provides a comprehensive range of services, including Shopify design, development, support and marketing. This partnership is a huge step forward in the e-commerce space, combining Vevol’s Shopify expertise and Syncio’s synchronization tech. It will help deliver…

WednesdayAug 07, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

The report explores the growth, competition, and consumer trends, for lesser known cannabinoids The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits,…

TuesdayAug 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”) CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform.…

MondayAug 05, 2024 10:00 am

Study Uncovers How Brain Tumors Evolve During Treatment

Glioblastoma multiforme is one of the most common brain cancers, primarily affecting an individual’s spine and/or brain. This malignant tumor forms from astrocytes, which support nerve cells. These tumors usually grow and spread very quickly, which creates pressure and destroys healthy tissue. In 2008, the glioblastoma multiforme genome was characterized by the Cancer Genome Atlas. Since then, scientists have directed their efforts toward examining transcriptomic and genomic data for new therapeutic targets that will improve patient clinical outcomes. Despite this, the five-year survival rates for this aggressive cancer remain below 5%. In a new study, scientists recently demonstrated how brain…

FridayAug 02, 2024 10:00 am

Data Gaps Which Need to Be Filled in Medicare Advantage

All beneficiaries of Medicare can enroll in Medicare Advantage as an alternative if they need private insurance. Currently, Medicare Advantage makes up over one-half all individuals enrolled in Medicare. Estimates from the Center for American progress show that the Centers for Medicare and Medicaid Services overpays Medicare Advantage plans by between 22% to 39%. This year, overpayments total between $83 billion and $127 billion. This is despite the fact that there’s no substantial evidence that this program promotes health equity for its enrollees or enhances health-care quality. Considering this, there is need for the Centers for Medicare and Medicaid Services…

WednesdayJul 31, 2024 10:00 am

Study Shows Autism More Prevalent in Kids Living in Congested Areas

Cases of neurodevelopmental disorders have increased globally in the last couple of years, with countries such as Italy observing a significant increase in cases of autism, noting that the disorder is more than four times higher in males than females. Autism spectrum disorder affects how individuals interact with others, as well as how they behave, learn and communicate. This disorder is said to have multifactorial origins, with recognized environmental and genetic triggers. Researchers posit that the period between fetal life through early childhood is the most vulnerable time for neurodevelopmental disorders. They argue that during this period, exposure to neurotoxic…